Lancemaside A Isolated from the Root of Codonopsis lanceolata Inhibits Ovarian Cancer Cell Invasion via the Reactive Oxygen Species (ROS)-Mediated p38 Pathway.

This study aimed to investigate the antimetastatic effects of lancemaside A, a major triterpenoid saponin, isolated from the roots of C. lanceolata, in human ovarian cancer cells. Lancemaside A significantly suppressed the migration and invasion and the expression of matrix metalloproteinases (MMPs)-2 and -9 in ovarian cancer A2780 and SKOV3 cells. Treatment with lancemaside A generated reactive oxygen species (ROS) in ovarian cancer cells. However, treatment with anti-oxidant N-acetyl-L-cysteine (NAC) significantly negated the anti-invasive activity of lancemaside A. Additionally, lancemaside A activated p38 MAP kinase, which is mediated by ROS generation. This is the first study, to our knowledge, to reveal that lancemaside A isolated from the roots of C. lanceolata exerts antimetastatic activity through inhibition of MMP expression and cancer cell invasion via activation of the ROS-mediated p38 pathway. PMID: 32471314 [PubMed - as supplied by publisher]
Source: The American Journal of Chinese Medicine - Category: Complementary Medicine Authors: Tags: Am J Chin Med Source Type: research

Related Links:

Vicky Jacobs, 48, created a multimedia campaign to raise awareness of the disease that was to take her life, ovarian cancer. The campaign features Kate Winslet who lost her mother Sally to the cancer.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
ConclusionsDetermining whether peritoneal carcinoma is serous carcinoma is important for therapy and prognostic prediction. In this case, we encountered a patient for whom surgery was chosen because of drug therapy resistance inferred through histological type estimation using the cell block method. Inferring the histological type by cell block preparation is useful for diagnosis and treatment selection.
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research
National advocacy group Black Women for Wellness joined more than 170 other nonprofits from 51 countries last week in demanding that Johnson &Johnson stop the worldwide distribution of its iconic Johnson’s Baby Powder. The demand for a global distribution ban stems from the potential for asbestos in talc, which has led to various cancers and thousands of personal injury lawsuits. A majority of talc cases pertain to women and ovarian cancer. A small percentage of the legal claims involve mesothelioma, a rare and aggressive cancer caused primarily by the inhalation or ingestion of asbestos fibers. Johnson &John...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Basel, 13 July 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly diagnosed advanced stage ovarian cancer. Topline safety data indicate that safety for Tecentriq in combination with Avastin, paclitaxel and carboplatin was consistent with the known safety profile of the combination.“Ovarian cancer remains one of the most aggressive cancers a...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Systematic retroperitoneal lymphadenectomy has been widely used in the surgical treatment of advanced ovarian cancer patients. Nevertheless, the corresponding therapeutic may not provide a survival benefit. Th...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
CONCLUSIONS: Secondary cytoreduction remains a viable treatment option for select patients for now, but this is entirely dependent on the highly anticipated overall survival results of DESKTOP III and SOC 1. PMID: 32649655 [PubMed - as supplied by publisher]
Source: Clinical Advances in Hematology and Oncology - Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research
Authors: O'Malley D PMID: 32649652 [PubMed - as supplied by publisher]
Source: Clinical Advances in Hematology and Oncology - Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research
Abstract BACKGROUND: Up to 70% of the patients with advanced ovarian cancer have a relapse after primary therapy. New agents and approaches are urgently needed to avoid or slow down the reccurence. OBJECTIVES: To investigate the efficacy of PARP inhibitors (PARPis) as maintenance treatment in patients with newly diagnosed advanced ovarian cancer. SEARCH STRATEGY: PubMed, Medline, Embase, Cochrane Library and Web of Science databases. SELECTION CRITERIA: All randomized clinical trials (RCTs) that compared PARPis and placebo as first-line maintenance therapy in ovarian cancer. DATA COLLECTION AND...
Source: BJOG : An International Journal of Obstetrics and Gynaecology - Category: OBGYN Authors: Tags: BJOG Source Type: research
Lung cancer is the second most common cancer in the United States with a 5-year relative survival rate of only 18 % [1]. A widely used non-small cell lung cancer (NSCLC) chemotherapy treatment is gemcitabine in combination with carboplatin which is also used in the treatment of other solid tumors such as bladder, ovarian and breast cancer. Gemcitabine/carboplatin treatment is known to cause severe toxicity that can lead to the need for postponed treatment, reduced doses and in some cases even discontinuation of treatment [2].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
More News: Acetylcysteine | Antidoxidants | Cancer | Cancer & Oncology | China Health | Complementary Medicine | Ovarian Cancer | Ovaries | Study